We square off with PhRMA, the trade group for the multinational pharmaceutical giants, in letters to The New York Times this week. At stake is treatment rationing, particularly for Hepatitis C. Will those who need treatment receive it?
We square off with PhRMA, the trade group for the multinational pharmaceutical giants, in letters to The New York Times this week. At stake is treatment rationing, particularly for Hepatitis C. Will those who need treatment receive it?